Ales

Researchers are evaluating how well laboratory data can estimate the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France. The study aims to see if the demand for care identified through lab tests matches the care provided by nephrologists, following recommendations from the French High Authority of Health. This study involves comparing laboratory data with patient records from nephrologists to verify the accuracy of identifying advanced chronic kidney disease cases. There are no specific treatments or interventions being tested in this study. Participants will be identified based on their laboratory data and nephrologist visits. The main outcome measured is the prevalence of stage 4 or higher chronic kidney disease over 12 months. No additional procedures or follow-ups are described, as this study focuses on data evaluation and comparison.

Colorectal cancer mainly affects elderly patients, with over half of new cases in France occurring in those aged 70 or older. Adjuvant chemotherapy has shown benefits in disease-free and overall survival after stage III colon cancer surgery, but its use in elderly patients remains limited. This phase III randomized study explores whether adjuvant chemotherapy improves disease-free survival in elderly patients and which chemotherapy regimen is most effective, addressing concerns about benefits for both unfit and fit elderly patients. Participants will be divided into two groups based on a multidisciplinary evaluation including a geriatrician. One group will receive fluoropyrimidine-based chemotherapy (LV5FU2 or capecitabine), and the other will receive oxaliplatin-based chemotherapy (FOLFOX4 or XELOX). Some patients may be assigned to observation only. Treatments will begin within 12 weeks after surgery. The study also evaluates specific biological markers common in elderly tumors, such as mismatch repair deficiency. During the study, participants will undergo assessments including geriatric questionnaires and medical monitoring. Researchers will track disease-free survival over three years following the last patient's enrollment. Safety and treatment effects will be monitored, with exclusion of patients expected to live less than four years or those unable to comply with follow-up. The study aims to better understand chemotherapy benefits in an elderly population after colon cancer surgery.